Advertisement

Pneumococcal Conjugate Vaccines Probe Studies: The Solution Points to the Problem

  • Ron Dagan
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 634)

Observed Versus Expected Effect of a Vaccine – The Vaccine Probe Concept

Understanding the effect of vaccines must include information derived from earlier studies (Phase I and Phase II), efficacy studies (Phase III), and data derived after introduction of the vaccines. When information is accumulated, one needs to assess to compare the ‘observed effects’ with what was expected from the vaccine (‘expected effects’). Observed effects can be divided schematically into five components (1) Observed outcomes that were expected to occur; (2) observed outcomes where no prevaccination estimates could be calculated, but some effect was still expected; (3) effect in contacts of vaccinees through herd immunity; (4) unexpected beneficial outcomes; and (5) unexpected deleterious effects. The term ‘vaccine probe’ is used to describe an attempt to understand pathogenesis, epidemiology, and disease burden through observing unexpected or unpredictable responses to vaccines.

When this approach is...

Keywords

Acute Otitis Medium Lower Respiratory Infection Invasive Pneumococcal Disease Pneumococcal Pneumonia Herd Immunity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bryce, J., Boschi-Pinto, C., Shibuya, K. and Black, R.E. (2005). WHO estimates of the causes of death in children. The Lancet, 365, 1147–1152.CrossRefGoogle Scholar
  2. Buttery, J.P., Riddell, A., McVernon, J., Chantler, T., Lane, L., Bowen-Morris, J., Diggle, L., Morris, R., Harnden, A., Lockhart, S., Pollard, A.J., Cartwright, K. and Moxon, E.R. (2005). Immunogenicity and safety of a combination pneumococcal–meningococcal vaccine in infants: a randomized controlled trial. JAMA 293, 1751–1758.PubMedCrossRefGoogle Scholar
  3. CDC. (2005). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998–2003. MMWR, 54, 893–897.Google Scholar
  4. Cherian, T., Mulholland, E.K., Carlin, J.B., Ostensen, H., Amin, R., de Campo, M., Greenberg, D., Lagos, R., Lucero, M., Madhi, S.A., O'Brien, K.L., Obaro, S. and Steinhoff, M.C. (2005). Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ, 83, 353–359.PubMedGoogle Scholar
  5. Cutts, F.T., Zaman, S.M., Enwere, G., Jaffar, S., Levine, O.S., Okoko, J.B., Oluwalana, C., Vaughan, A., Obaro, S.K., Leach, A., McAdam, K.P., Biney, E., Saaka, M., Onwuchekwa, U., Yallop, F., Pierce, N.F., Greenwood, B.M. and Adegbola, R.A. (2005). Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. The Lancet, 365, 365–1146.CrossRefGoogle Scholar
  6. Dagan, R., Givon-Lavi, N., Abu-Abed, J., Rosenblum, H. and Greenberg, D. (2007). Nasopharyngeal pneumococcal carriage in first year of life following administration of two or three doses of 7-valent CRM-conjugate vaccine [G-1241]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17–20, 2007, Chicago, IL.Google Scholar
  7. Dagan, R., Sikuler-Cohen, M., Zamir, O., Janco, J., Givon-Lavi, N. and Fraser, D. (2001). Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr. Infect. Dis. J., 20, 20–958.Google Scholar
  8. Fireman, B., Black, S.B., Shinefield, H.R., Lee, J., Lewis, E. and Ray, P. (2003). Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22, 22–16.CrossRefGoogle Scholar
  9. Goldblatt, D., Southern, J., Ashton, L., Richmond, P., Burbidge, P., Tasevska, J., Crowley-Luke, A., Andrews, N., Morris, R., Borrow, R., Cartwright, K. and Miller, E. (2006). Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 25, 25–319.CrossRefGoogle Scholar
  10. Grijalva, C.G., Nuorti, J.P., Arbogast, P.G., Martin, S.W., Edwards, K.M. and Griffin, M.R. (2007). Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369, 369–1186.CrossRefGoogle Scholar
  11. Hicks, L.A., Harrison, L.H., Flannery, B., Hadler, J.L., Schaffner, W., Craig, A.S., Jackson, D., Thomas, A., Beall, B., Lynfield, R., Reingold, A., Farley, M.M. and Whitney, C.G. (2007). Incidence of Pneumococcal Disease Due to Non-Pneumococcal Conjugate Vaccine (PCV7) Serotypes in the United States during the Era of Widespread PCV7 Vaccination, 1998–2004. J. Infect. Dis. 196, 196–1354.CrossRefGoogle Scholar
  12. Lexau, C.A., Lynfield, R., Danila, R., Pilishvili, T., Facklam, R., Farley, M.M., Harrison, L.H., Schaffner, W., Reingold, A., Bennett, N.M., Hadler, J., Cieslak, P.R. and Whitney, C.G. (2005). Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294, 294–2051.CrossRefGoogle Scholar
  13. Lockhart, S.P., Hackell, J.G. and Fritzell, B. (2006). Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev. Vaccines, 5, 5–564.CrossRefGoogle Scholar
  14. Madhi, S.A. and Klugman, K.P. (2007). World Health Organisation definition of “radiologically-confirmed pneumonia” may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 25, 25–2419.CrossRefGoogle Scholar
  15. Madhi, S.A., Klugman, K.P. and The Vaccine Trialist, G. (2004). A role for Streptococcus pnemoniae in virus-associated pneumonia. Nat. Med. 10, 10–813.CrossRefGoogle Scholar
  16. Madhi, S.A., Kuwanda, L., Cutland, C. and Klugman, K.P. (2005). The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin. Infect. Dis. 40, 40–1518.CrossRefGoogle Scholar
  17. Madhi, S.A., Ludewick, H., Kuwanda, L., Niekerk, N., Cutland, C., Little, T. and Klugman, K.P. (2006). Pneumococcal coinfection with human metapneumovirus. J. Infect. Dis. 193, 193–1243.CrossRefGoogle Scholar
  18. Rudan, I., Tomaskovic, L., Boschi-Pinto, C. and Campbell, H. (2004). Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull. World Health Organ. 82, 82–903.Google Scholar
  19. Salt, P., Banner, C., Oh, S., Yu, L.M., Lewis, S., Pan, D., Griffiths, D., Ferry, B. and Pollard, A. (2007). Social mixing with other children during infancy enhances antibody response to a pneumococcal conjugate vaccine in early childhood. Clin. Vaccine Immunol. 14, 14–599.CrossRefGoogle Scholar
  20. Veenhoven, R., Bogaert, D., Uiterwaal, C., Brouwer, C., Kiezebrink, H., Bruin, J., lJzerman, E., Hermans, P., de Groot, R., Zegers, B., Kuis, W., Rijkers, G., Schilder, A. and Sanders, E. (2003). Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. The Lancet, 361, 361–2195.CrossRefGoogle Scholar
  21. Whitney, C.G., Farley, M.M., Hadler, J., Harrison, L.H., Bennett, N.M., Lynfield, R., Reingold, A., Cieslak, P.R., Pilishvili, T., Jackson, D., Facklam, R.R., Jorgensen, J.H. and Schuchat, A. (2003). Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 348–1746.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Pediatric Infectious Disease UnitSoroka University Medical CenterIsrael

Personalised recommendations